Herpes and pox viral complement control proteins: 'The mask of self'

Trends in Immunology

Volumn 24, Issue 9, 2003, Pages 500-507

  Mullick, Jayati ^a   Kadam, Archana ^a   Sahu, Arvind ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; VIRUS PROTEIN;

COMPLEMENT SYSTEM; COVALENT BOND; DISEASE COURSE; GENE FUNCTION; GENE STRUCTURE; GENETIC IDENTIFICATION; HERPES; HERPES VIRUS; HUMAN; IMMUNITY; IN VIVO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PATHOGENESIS; POXVIRUS; REVIEW;

EID: 0042881066     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00207-2     Document Type: Review

References (56)

1. Cooper N.R. Complement and viruses. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;393-407 Marcel Dekker.
2. Bernet J., et al. Viral mimicry of the complement system. J. Biosci. 28:2003;249-264.
3. Sahu A., Lambris J.D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180:2001;35-48.
4. Da Costa X.J., et al. Humoral response to herpes simplex virus is complement-dependent. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12708-12712.
5. Ochsenbein A.F., Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity. Immunol. Today. 21:2000;624-630.
6. Kopf M., et al. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 8:2002;373-378.
7. Suresh M., et al. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J. Immunol. 170:2003;788-794.
8. Janeway C.A. Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
9. Lu J., et al. Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. Biochim. Biophys. Acta. 1572:2002;387-400.
10. Pangburn M.K., Müller-Eberhard H.J. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152:1980;1102-1114.
11. Sahu A., et al. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 302:1994;429-436.
12. Sahu A., et al. Complement inhibitors targeting C3, C4, and C5. Lambris J.D., Holers V.M., et al. Therapeutic Interventions in the Complement System. 2000;75-112 Humana Press.
13. Friedman H.M., et al. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 309:1984;633-635.
14. Frink R.J., et al. Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C. J. Virol. 45:1983;634-647.
15. Johnson D.C., Spear P.G. O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus. Cell. 32:1983;987-997.
16. Kostavasili I., et al. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 158:1997;1763-1771.
17. Fries L.F., et al. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J. Immunol. 137:1986;1636-1641.
18. Hung S.L., et al. Structural basis of C3b binding by glycoprotein-C of herpes simplex virus. J. Virol. 66:1992;4013-4027.
19. Huemer H.P., et al. Species selective interaction of alphaherpesvirinae with the unspecific immune system of the host. Arch. Virol. 130:1993;353-364.
20. Huemer H.P., et al. Cloning and expression of the complement receptor glycoprotein C from Herpesvirus simiae (herpes B virus): protection from complement-mediated cell lysis. J. Gen. Virol. 84:2003;1091-1100.
21. Russo J.J., et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U. S. A. 93:1996;14862-14867.
22. Mold C., et al. Epstein-Barr virus regulates activation and processing of the third component of complement. J. Exp. Med. 168:1988;949-969.
23. Kapadia S.B., et al. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73:1999;7658-7670.
24. Fodor W.L., et al. The complement control protein homolog of Herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69:1995;3889-3892.
25. Means R.E., et al. Kaposi's sarcoma associated herpesvirus immune evasion strategi es. Front. Biosci. 7:2002;e185-e203.
26. Carroll M.C. The role of complement in B cell activation and tolerance. Adv. Immunol. 74:2000;61-88.
27. Molina H., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3357-3361.
28. Wolffe E.J., et al. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67:1993;4732-4741.
29. Mullick J., et al. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 77:2003;3878-3881.
30. Sahu A., Pangburn M.K. Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol. 30:1993;679-684.
31. Spiller O.B., et al. Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J. Biol. Chem. 278:2003;9283-9289.
32. Rother R.P., et al. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of Herpesvirus saimiri. J. Virol. 68:1994;730-737.
33. Smith S.A., Kotwal G.J. Immune response to poxvirus infections in various animals. Crit. Rev. Microbiol. 28:2002;149-185.
34. Moss B., Shisler J.L. Immunology 101 at poxvirus U: immune evasion genes. Semin. Immunol. 13:2001;59-66.
35. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:2003;36-50.
36. Smith G.L. Vaccinia virus immune evasion. Immunol. Lett. 65:1999;55-62.
37. Kotwal G.J., Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature. 335:1988;176-178.
38. Kotwal G.J., et al. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science. 250:1990;827-830.
39. McKenzie R., et al. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166:1992;1245-1250.
40. 1 inactivates the alternative complement pathway. J. Immunol. 160:1998;5596-5604.
41. Smith S.A., et al. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J. Virol. 74:2000;5659-5666.
42. Wiles A.P., et al. NMR studies of a viral protein that mimics the regulators of complement activation. J. Mol. Biol. 272:1997;253-265.
43. Murthy K.H., et al. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell. 104:2001;301-311.
44. Oran A.E., Isenman D.E. Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J. Biol. Chem. 274:1999;5120-5130.
45. Rosengard A.M., et al. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8808-8813.
46. Liszewski M.K., et al. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J. Biol. Chem. 275:2000;37692-37701.
47. Krych M., et al. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor, CD35) by substitution mutagenesis. J. Biol. Chem. 269:1994;13273-13278.
48. Isaacs S.N., et al. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U. S. A. 89:1992;628-632.
49. McNearney T.A., et al. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J. Exp. Med. 166:1987;1525-1535.
50. Lubinski J.M., et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72:1998;8257-8263.
51. Kapadia S.B., et al. Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. Immunity. 17:2002;143-155.
52. Al Mohanna F., et al. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation. 71:2001;796-801.
53. Lubinski J., et al. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190:1999;1637-1646.
54. Wetsel R.A. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7:1995;48-53.
55. Stoiber H., et al. Role of complement in HIV infection. Annu. Rev. Immunol. 15:1997;649-674.
56. Miller C.G., et al. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology. 229:1997;126-133.